Stockreport

How Positive Cretostimogene Trial Updates And Leadership Moves At CG Oncology (CGON) Have Changed Its Investment Story [Yahoo! Finance]

CG Oncology, Inc. - Common stock  (CGON) 
PDF CG Oncology has reported positive topline data from its BOND-003 and CORE-008 trials of investigational oncolytic immunotherapy cretostimogene in high-risk non-muscle in [Read more]